Phase 1 Marginal Zone Lymphoma Clinical Trials
23 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–20 of 23 trials
Recruiting
Phase 1
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+6 more
Nurix Therapeutics, Inc.572 enrolled62 locationsNCT05131022
Recruiting
Phase 1
Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+4 more
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.85 enrolled9 locationsNCT06980116
Recruiting
Phase 1Phase 2
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies
Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines645 enrolled130 locationsNCT05006716
Recruiting
Phase 1
Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaRecurrent Diffuse Large B-Cell Lymphoma+16 more
City of Hope Medical Center37 enrolled1 locationNCT06859008
Recruiting
Phase 1Phase 2
Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 1Phase 2
Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma
Diffuse Large B Cell LymphomaHodgkin LymphomaMantle Cell Lymphoma+6 more
New York Medical College20 enrolled1 locationNCT04491370
Recruiting
Phase 1
SynKIR-310 for Relapsed/Refractory B-NHL
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaDLBCL - Diffuse Large B Cell Lymphoma+23 more
Verismo Therapeutics36 enrolled5 locationsNCT06544265
Recruiting
Phase 1Phase 2
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaChronic Lymphocytic Leukemia+10 more
Vironexis Biotherapeutics Inc.32 enrolled9 locationsNCT06533579
Recruiting
Phase 1
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
Diffuse Large B-Cell Lymphoma (DLBCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)+5 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Phase 1
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaNon-Hodgkin Lymphoma+7 more
Marcela V. Maus, M.D.,Ph.D.24 enrolled1 locationNCT06026319
Recruiting
Phase 1
LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies
Diffuse Large B Cell LymphomaNon-Hodgkin LymphomaMantle Cell Lymphoma+3 more
Medical College of Wisconsin12 enrolled1 locationNCT05990465
Recruiting
Phase 1Phase 2
CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies
Diffuse Large B Cell LymphomaFollicular LymphomaMarginal Zone Lymphoma+5 more
Medical College of Wisconsin100 enrolled1 locationNCT04186520
Recruiting
Phase 1
Study of SGR-1505 in Mature B-Cell Neoplasms
High-grade B-cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+23 more
Schrödinger, Inc.98 enrolled36 locationsNCT05544019
Recruiting
Phase 1
B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies
Recurrent Chronic Lymphocytic LeukemiaRecurrent Follicular LymphomaRecurrent Small Lymphocytic Lymphoma+12 more
Mayo Clinic27 enrolled1 locationNCT06191887
Recruiting
Phase 1
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Diffuse Large B Cell LymphomaMantle Cell LymphomaFollicular Lymphoma+4 more
Newave Pharmaceutical Inc60 enrolled4 locationsNCT04775745
Recruiting
Phase 1
This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin Lymphoma
DLBCL - Diffuse Large B Cell LymphomaFollicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)+2 more
LTZ Therapeutics, Inc.42 enrolled5 locationsNCT07121946
Recruiting
Phase 1Phase 2
A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin Lymphoma
Follicular LymphomaMarginal Zone Lymphoma
Enterome80 enrolled12 locationsNCT04669171
Recruiting
Phase 1
Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Mantle Cell LymphomaFollicular LymphomaSplenic Marginal Zone Lymphoma+3 more
UNC Lineberger Comprehensive Cancer Center20 enrolled1 locationNCT04223765
Recruiting
Phase 1
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaMantle Cell Lymphoma+5 more
Carna Biosciences, Inc.120 enrolled13 locationsNCT05602363
Recruiting
Phase 1Phase 2
A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+5 more
CRISPR Therapeutics AG120 enrolled7 locationsNCT05643742